1
|
Shanmugam Anuratha K, Su YZ, Wang PJ, Hasin P, Wu J, Hsieh CK, Chang JK, Lin JY. Free-standing 3D core-shell architecture of Ni 3S 2@NiCoP as an efficient cathode material for hybrid supercapacitors. J Colloid Interface Sci 2022; 625:565-575. [PMID: 35749851 DOI: 10.1016/j.jcis.2022.06.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Revised: 05/26/2022] [Accepted: 06/04/2022] [Indexed: 12/01/2022]
Abstract
The design and discovery of free-standing hybrid electrode materials with large absolute capacity and high cycling stability for energy storage become desirable and are still challenging. In this work, we demonstrate that the hybrid supercapacitor (HSC) device is assembled by 3D core-shell hierarchical nanorod arrays of Ni3S2@NiCoP nanocomposite for the first time. The Ni3S2@NiCoP nanocomposite is successfully synthesized through a facile stratagem containing hydrothermal process and the subsequent electrodeposition method. The 3D architecture of Ni3S2@NiCoP hybrid electrode composed of vertically aligned "hyperchannel" 1D Ni3S2 nanorods and highly conductive interconnected 2D nanosheets of NiCoP is beneficial to fast electron transfer kinetics, thus leading to enhancing the ionic and electronic conductivity, kinetics of redox reaction, and synergistic behavior of active species. The fabricated HSC device with Ni3S2@NiCoP electrode delivers outstanding areal capacity of 109 µAh cm-2 at a current density of 1 mA cm-2, brilliant energy density of 74.9 Wh kg-1 at a power density of 700 W kg-1, and prominent cyclic performance of 92% capacity retention even after 144-h floating test. This work demonstrates that the core-shell hierarchical nanorod arrays of Ni3S2@NiCoP can be viewed as one of the novel battery-type electrode materials for high-performance HSCs.
Collapse
Affiliation(s)
| | - Ying-Zhou Su
- Department of Chemical Engineering and Biotechnology, Tatung University, Taipei City 104, Taiwan
| | - Po-Jen Wang
- Department of Chemical Engineering and Biotechnology, Tatung University, Taipei City 104, Taiwan
| | - Panitat Hasin
- Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Ministry of Higher Education, Science, Research and Innovation, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand
| | - Jihuai Wu
- Eng. Res. Centre of Environment-Friendly Functional Materials, Ministry of Education, Fujian Eng. Res. Centre of Green Functional Materials, Huaqiao Univ., Xiamen 361021, China
| | - Chien-Kuo Hsieh
- Department of Materials Engineering, Ming Chi University of Technology, New Taipei City 24301, Taiwan.
| | - Jeng-Kuei Chang
- Department of Materials Science and Engineering, National Yang Ming Chiao Tung University, Hsinchu 300093, Taiwan
| | - Jeng-Yu Lin
- Department of Chemical and Materials Engineering, Tunghai University, Taichung City 40704, Taiwan.
| |
Collapse
|
2
|
Su YZ, Wang CB, Zhou Y, Sun NT. Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients. Genet Mol Res 2015; 14:5181-7. [PMID: 26125711 DOI: 10.4238/2015.may.18.8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The present study aimed to explore the changes in serum endostatin and fibroblast growth factor 19 (FGF-19) in acute myeloid leukemia patients, and to determine their effects on chemotherapeutic sensitivity. Sixty acute myeloid leukemia patients and 30 healthy controls were included in the study. Patient serum endostatin and FGF-19 levels were measured on admission, and then, standard chemotherapy was administered. The patients were divided into 2 groups according to chemotherapeutic effects: 21 patients in the chemotherapeutic sensitivity group (complete remission + partial remission) and 39 in the chemotherapeutic resistance group (no remission + degradation). A receiver operating characteristic (ROC) curve was used to analyze the relationship of serum endostatin and FGF-19 levels with chemotherapeutic sensitivity in acute myeloid leukemia patients. The levels of serum endostatin and FGF-19 in acute myeloid leukemia patients before chemotherapy were significantly higher than those in the control group. Moreover, these levels significantly decreased after chemotherapy (P < 0.01). The levels of serum endostatin and FGF-19 in the chemotherapeutic sensitivity group were lower than those in the chemotherapeutic resistance group, both before and after chemotherapy (P < 0.05 and P < 0.01, respectively). ROC curve analysis showed that the predictive values of endostatin and FGF-19 were good, and there was no significant difference between these results. In conclusion, serum endostatin and FGF-19 can be used as predictors of chemotherapeutic sensitivity for acute myeloid leukemia patients, and may be important for determining prognosis.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Pharmacological/blood
- Case-Control Studies
- Cytarabine/therapeutic use
- Daunorubicin/therapeutic use
- Drug Resistance, Neoplasm/genetics
- Endostatins/blood
- Endostatins/genetics
- Female
- Fibroblast Growth Factors/blood
- Fibroblast Growth Factors/genetics
- Gene Expression
- Harringtonines/therapeutic use
- Homoharringtonine
- Humans
- Idarubicin/therapeutic use
- Leukemia, Myeloid, Acute/blood
- Leukemia, Myeloid, Acute/drug therapy
- Leukemia, Myeloid, Acute/genetics
- Leukemia, Myeloid, Acute/pathology
- Male
- Middle Aged
- Prognosis
- ROC Curve
- Remission Induction
- Treatment Outcome
Collapse
Affiliation(s)
- Y Z Su
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - C B Wang
- Department of Tumor and Hematology, Yancheng Hospital Affiliated to Southeast University (The Third People's Hospital of Yancheng), Yancheng, China
| | - Y Zhou
- Department of Tumor and Hematology, Yancheng Hospital Affiliated to Southeast University (The Third People's Hospital of Yancheng), Yancheng, China
| | - N T Sun
- Department of Tumor and Hematology, Yancheng Hospital Affiliated to Southeast University (The Third People's Hospital of Yancheng), Yancheng, China
| |
Collapse
|
3
|
Tao HF, Liu YS, Fang JL, Su YZ, Chen FH, Zhou LY, Zhu YS. Significance of SODD expression in childhood acute lymphoblastic leukemia and its influence on chemotherapy. Genet Mol Res 2014; 13:2020-31. [PMID: 24737427 DOI: 10.4238/2014.march.24.6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
This study explored the clinical significance of silencer of death domain (SODD) expression in childhood acute lymphoblastic leukemia (ALL) and its influence on chemotherapy as well as the effect of SODD expression on apoptosis of leukemic cells. The expression of SODD proteins in different ALL groups was determined by immunocytochemistry. The SODD RNAi-interfering plasmid was constructed and transferred to Jurkat cells, and the effects of SODD expression on cell proliferation and apoptosis were analyzed using the MTT and FCM methods. The expressions of SODD, Phospho-NF-κB-P65, Bcl-2, and Caspase 3 were detected by Western blot analysis. The expression of SODD proteins was significantly higher in the ALL groups than in the control group (P < 0.05). The positive expression rate of SODD was significantly higher in refractory/relapsed and clinical high-risk groups than in standard-risk, initial treatment, and complete remission groups (P < 0.05). Microtubule-targeting drugs such as vincristine and taxol can notably down-regulate SODD expression during apoptosis, whereas DNR, and Ara-c cannot. The sensitivity of Jurkat cells to chemotherapeutic drugs increased with down-regulated SODD expression induced by SODD-interfering plasmid transfection. The sensitivity of the cells transfected with SODD-cloning genes decreased. SODD expression was high in the ALL children. These findings indicated that SODD over-expression might be correlated with the clinical classification, curative effect, and prognosis of ALL cells. Microtubule-targeting drugs can specifically down-regulate SODD expression in leukemic cells, thereby increasing the sensitivity of leukemic cells to SODD-targeting chemotherapeutics. In contrast, increased SODD expression tends to reduce sensitivity.
Collapse
Affiliation(s)
- H F Tao
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Y S Liu
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - J L Fang
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Y Z Su
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - F H Chen
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - L Y Zhou
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| | - Y S Zhu
- Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
| |
Collapse
|
4
|
Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH, Weiss MH, Couldwell WT. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg 1996; 85:329-34. [PMID: 8755764 DOI: 10.3171/jns.1996.85.2.0329] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Protein kinase C (PKC) is an enzyme involved in the regulation of cellular growth, proliferation, and differentiation in a number of tissues including the anterior pituitary, in which it is also believed to play a role in hormone secretion. Protein kinase C activity and expression have been found to be greater in adenomatous pituitary cells than in normal human and rat pituitary cells and higher in invasive pituitary tumor cells than in noninvasive ones. Inhibition of PKC activity has been shown in a variety of tumor cells to inhibit growth in a dose-related fashion. The purpose of the current study was to determine whether hypericin, a potent inhibitor of PKC activity that may be administered clinically, alters the growth and proliferation in established pituitary adenoma lines and to determine if inhibition of PKC activity induces apoptosis, as reported in some other tumor cell types. Two established pituitary adenoma cell lines, AtT-20 and GH4C1, were treated with hypericin in tissue culture for defined periods following passage. Inhibition of growth was found to be dose dependent in all three cell lines in low micromolar concentrations of hypericin, as determined by viable cell counts, methylthiotetrazole assay, and [3H]thymidine uptake studies. Concentrations of hypericin as low as 100 nM also induced apoptosis in these established lines, whereas treatment of normal human fibroblasts with a concentration of 10 microM failed to induce apoptosis. The potential use of hypericin in the therapy of pituitary adenomas warrants additional in vitro investigations with the aim of later moving toward therapeutic trials in selected patients in whom surgical or medical therapy has failed.
Collapse
Affiliation(s)
- H B Hamilton
- Department of Neurosurgery, University of Southern California School of Medicine, Los Angeles, USA
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH, Su YZ. Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer 1993; 53:478-85. [PMID: 8094074 DOI: 10.1002/ijc.2910530321] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Two drug-resistant sublines, CP2.0 and RT, were simultaneously selected by cis-diamminedichloroplatinum (CDDP) from the human colon carcinoma cell line LoVo by the conventional method of continuous drug exposure. The 2 sublines differed in morphology, growth kinetics and pattern of gene expression. Genetic signature analysis indicated that the lines were independent subclones but that both arose from LoVo. These sublines were maintained in a growth medium containing 2.0 micrograms/ml CDDP. However, CP2.0 cells were 3 times more resistant to CDDP than were RT cells. Although both were cross-resistant to mustargen and 5-fluorouracil, only CP2.0 was resistant to Adriamycin and vincristine. Western-blot analysis, immunocytochemical staining and in vitro phosphorylation experiments indicated that the level of P-glycoprotein was significantly elevated in CP2.0 but not in RT. Despite the differences between these sublines, they possess similar CDDP-resistance mechanisms, including decreased intracellular CDDP accumulation, elevated levels of glutathione and metallothionein-like proteins, increased glutathione transferase-pi mRNA, and enhanced susceptibility to CDDP cytotoxicity after treatment with DL-buthionine-[S,R]-sulfoximine. Nevertheless, our results suggest that, in certain tumor types, P-glycoprotein-mediated multi-drug resistance and CDDP-resistance phenotypes can coexist in cells with primary resistance to CDDP.
Collapse
Affiliation(s)
- L Y Yang
- Division of Laboratory Medicine, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | | | |
Collapse
|
6
|
Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM. 2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993; 67:10-4. [PMID: 8094002 PMCID: PMC1968239 DOI: 10.1038/bjc.1993.3] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of this agent in vitro and compared its relative cytotoxicity with that of other antineoplastic agents in current clinical use. Comparisons were conducted against nitrogen mustard, doxorubicin, vincristine and cytosine arabinoside. Our results indicate that 2-CDA has activity in myeloid and many lymphoid neoplasms but that multiple myeloma specimens reveal significant resistance. Cross resistance studies reveal a correlation between 2-CDA and the alkylator nitrogen mustard but no correlation between 2-CDA and doxorubicin, vincristine nor cytosine arabinoside. The results suggest 2-CDA activity in many human hematologic neoplasms with the clear exception of multiple myeloma and further suggest a relationship between this agent and alkylators of the mustard class. The DiSC assay may provide useful insights in the pre-clinical evaluation of new antineoplastic drugs and may help to elucidate drug activities and mechanisms of action.
Collapse
Affiliation(s)
- R A Nagourney
- Memorial Cancer Institute, Long Beach, California 90806
| | | | | | | | | |
Collapse
|
7
|
Yang LY, Trujillo JM, Su YZ. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells. Anticancer Res 1992; 12:473-9. [PMID: 1349796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/25/2023]
Abstract
We previously reported that two multidrug resistant sublines, AdR1.2 and SRA1.2, derived from LoVo human colon carcinoma cells, apparently expressed different resistance phenotypes including differential expression of p-glycoprotein (Pgp). Here, we further examined and compared other potential resistance mechanisms between AdR1.2 and SRA1.2 resistant cells. Our results showed that the Pgp-mediated AdR1.2 cells possessed an activated drug efflux pump and decreased nucleus binding of Adriamycin, while the non-Pgp-mediated SRA1.2 cells only held the second feature. Verapamil, however, partially reversed resistance in both sublines. Although glutathione-s-transferase was overexpressed in AdR1.2 but not in SRA1.2, both sublines had lower susceptibilities to drug-induced DNA strand breaks and greater capacities to repair such damage than did LoVo cells. These data suggest that, despite the differences in multidrug resistance phenotypes, the features of decreased susceptibility to DNA damage and enhanced DNA repair capacities may represent the common mechanisms responsible for drug resistance in both Pgp- and non-Pgp-mediated multidrug resistant cells.
Collapse
Affiliation(s)
- L Y Yang
- Division of Laboratory Medicine, University of Texas, M.D. Anderson Cancer Center, Houston 77030
| | | | | |
Collapse
|
8
|
Trujillo JM, Yang LY, Gercovich G, Su YZ. Heterogeneous effects of interferon on antitumor agents' cytotoxicities to human colon carcinoma cell lines. Anticancer Res 1991; 11:439-44. [PMID: 1902077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Six established human colon carcinoma cell lines that segregated into three groups with different degrees of differentiation were treated using three subclasses of interferons as single agents and in combination with either 5-fluorouracil, cis-platinum, or adriamycin. The cytotoxicities of the combination treatments were heterogeneous and did not relate to the cell's levels of differentiation. Our data suggest that the optimal combinations of interferons and chemotherapeutic agents are independent of the differentiation state of the colon cancer cells.
Collapse
Affiliation(s)
- J M Trujillo
- Division of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | |
Collapse
|
9
|
Trujillo JM, Yang LY, Gercovich G, Su YZ, Lee J. Metronidazole enhances the cytotoxic synergism produced by the combination of 1-beta-arabinofuranosylcytosine and cis-diamminedichloroplatinum. Anticancer Res 1989; 9:1751-6. [PMID: 2627125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Metronidazole (MZ) was evaluated as a single agent or in combination with CDDP and araC for its cytotoxic effects on five established human colon carcinoma cell lines. MZ alone produced little cytotoxicity at 1 h drug incubation. The cytotoxicity was detectable only after 2 h incubation and increased as a function of duration of treatment, suggesting a time-dependent rather than a dose-dependent cytotoxic effect. MZ had no effect on CDDP- or araC-induced cytotoxicity, whereas MZ enhanced the synergism resulting from the combination of two antitumor agents on the human colon tumor cell lines tested. Such enhancement was more pronounced on cells growing in stationary rather than in exponential phase. MZ not only produced a reversible S-phase arrest but also lessened the CDDP-produced inhibition on the incorporation of araC into DNA. However, it did not enhance CDDP-induced DNA cross-linkings, with or without araC. Our results indicated that MZ enhanced the synergism produced by two antitumor drugs in combination and that enhancement was accompanied by an increase in S-phase population and of the incorporation of araC into nucleic acids.
Collapse
Affiliation(s)
- J M Trujillo
- Division of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston 77030
| | | | | | | | | |
Collapse
|
10
|
Weisenthal LM, Su YZ, Duarte TE, Dill PL, Nagourney RA. Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C. Cancer Treat Rep 1987; 71:1239-43. [PMID: 3480042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Fresh specimens of human lymphatic neoplasms were tested with the differential staining cytotoxicity assay. Cells from relapsed patients with acute lymphoblastic leukemia (ALL) were significantly more resistant to vincristine, dexamethasone, and doxorubicin in the assay than were cells from previously untreated patients. The putative C kinase inhibitors verapamil (V), imipramine (I), lidocaine (L), tamoxifen (T), chlorpromazine (C), and haloperidol (H) were then tested singly, in combination with each other (VILTCH, ITCH, and VL), and in combination with vincristine. At concentrations judged to be clinically achievable, VILTCH itself was occasionally toxic to ALL and chronic lymphocytic leukemia. The VILTCH combination clearly potentiated the cytotoxic activity of vincristine in five of eight ALL specimens from relapsed patients and potentiated vincristine in 18 of 30 chronic lymphocytic leukemia specimens. It also potentiated vincristine in two of six specimens of multiple myeloma and five of six specimens of non-Hodgkin's lymphoma. The VILTCH combination had no significant effects in fresh cultures of normal human lymphocytes. The most active drugs in the VILTCH combination appeared to be verapamil and lidocaine. We conclude that the differential staining cytotoxicity assay is a useful tool to study the circumvention of clinically acquired drug resistance. While the mechanism of the observed enhancement of the cytotoxic effects of vincristine is not known, it is possible that combinations of putative C kinase inhibitors may reduce drug resistance in human lymphatic neoplasms.
Collapse
|
11
|
Su YZ, Duarte TE, Dill PL, Weisenthal LM. Selective enhancement by menadiol of in vitro drug activity in human lymphatic neoplasms. Cancer Treat Rep 1987; 71:619-25. [PMID: 3581100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The effect of menadiol (vitamin K3) on fresh specimens of human lymphatic neoplasms (HLN) was tested by means of the differential staining cytotoxicity assay. Menadiol was tested alone and in combination with standard antineoplastic agents. Drug effects were then compared with the effects of the same drugs in normal human lymphocytes and in fresh specimens of human non-small cell lung cancer. By itself, menadiol was moderately toxic to HLN, but not to normal lymphocytes or non-small cell lung cancer. Menadiol, menadione, and two structurally related congeners were equitoxic to HLN cells, but sodium metabisulfite (present in menadiol solutions as a preservative) was nontoxic. Menadiol increased the cytotoxic effects of a number of standard agents in HLN but not in normal lymphocytes. Cell survival times with mechlorethamine, vincristine, and dexamethasone were converted from a range characteristic of drug resistance (ie, range observed in relapsed patients) to a range characteristic of drug sensitivity (ie, range observed in untreated patients) in the presence of menadiol. These effects occurred at a concentration (2.0 micrograms/ml; 4.7 microM) of menadiol which is probably clinically achievable and which did not deplete intracellular glutathione. Menadiol should receive clinical testing as a chemosensitizing agent in HLN.
Collapse
|
12
|
Su YZ, Pan QC. [Chemosensitivity assay in acute leukemia]. Zhonghua Nei Ke Za Zhi 1985; 24:523-6, 572-3. [PMID: 3866683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
13
|
Su YZ, Pan QC, Sun MZ, Ren YF. [Structure-activity relationship of hexamethylmelamine derivatives]. Zhongguo Yao Li Xue Bao 1983; 4:276-80. [PMID: 6230876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|